De novo design of miniprotein agonists and antagonists targeting G protein-coupled receptors.

从头设计靶向 G 蛋白偶联受体的微型蛋白激动剂和拮抗剂

阅读:5
作者:Muratspahić Edin, Feldman David, Kim David E, Qu Xiangli, Bratovianu Ana-Maria, Rivera-Sánchez Paula, Dimitri Federica, Cao Jason, Cary Brian P, Belousoff Matthew J, Keov Peter, Chen Qingchao, Ren Yue, Fine Justyn, Sappington Isaac, Schlichthaerle Thomas, Zhang Jason Z, Pillai Arvind, Mihaljević Ljubica, Bauer Magnus, Torres Susana Vázquez, Motmaen Amir, Lee Gyu Rie, Tran Long, Wang Xinru, Goreshnik Inna, Vafeados Dionne K, Svendsen Justin E, Hosseinzadeh Parisa, Lindegaard Nicolai, Brandt Matthäus, Waltenspühl Yann, Deibler Kristine, Oostdyk Luke, Cao William, Anantharaman Lakshmi, Stewart Lance, Halloran Lauren, Spangler Jamie B, Sexton Patrick M, Roth Bryan L, Krumm Brian E, Wootten Denise, Tate Christopher G, Norn Christoffer, Baker David
G protein-coupled receptors (GPCRs) play key roles in physiology and are central targets for drug discovery and development, yet the design of protein agonists and antagonists has been challenging as GPCRs are integral membrane proteins and conformationally dynamic. Here we describe computational de novo design methods and a high throughput "receptor diversion" microscopy-based screen for generating GPCR binding miniproteins with high affinity, potency and selectivity, and the use of these methods to generate MRGPRX1 agonists and CXCR4, GLP1R, GIPR, GCGR and CGRPR antagonists. Cryo-electron microscopy data reveals atomic-level agreement between designed and experimentally determined structures for CGRPR-bound antagonists and MRGPRX1-bound agonists, confirming precise conformational control of receptor function. Our de novo design and screening approach opens new frontiers in GPCR drug discovery and development.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。